May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Effect of betamethasone phosphate–loaded polyactide nanoparticles on experimental autoimmune uveoretinitis
Author Affiliations & Notes
  • T. Sakai
    Ophthalmology,
    Jikei university school of medicine, Tokyo, Japan
  • H. Kohno
    Ophthalmology,
    Jikei university school of medicine, Tokyo, Japan
  • K. Kitahara
    Ophthalmology,
    Jikei university school of medicine, Tokyo, Japan
  • S. Saito
    Molecular immunology,
    Jikei university school of medicine, Tokyo, Japan
  • T. Ishihara
    DDS institute,
    Jikei university school of medicine, Tokyo, Japan
  • Y. Mizushima
    DDS institute,
    Jikei university school of medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships  T. Sakai, None; H. Kohno, None; K. Kitahara, None; S. Saito, None; T. Ishihara, None; Y. Mizushima, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3958. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Sakai, H. Kohno, K. Kitahara, S. Saito, T. Ishihara, Y. Mizushima; Effect of betamethasone phosphate–loaded polyactide nanoparticles on experimental autoimmune uveoretinitis . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3958.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effects of betamethasone phosphate–loaded polyactide nanoparticles (BP–PLA NPs) on experimental autoimmune uveoretinitis (EAU) in Lewis rats. Methods: EAU was induced in Lewis rats with S–Ag. Saline (n=5), betamethasone phosphate (BP) (n=5), or BP–PLA NPs (n=5) were injected intravenously on the day of disease onset. Eyes were removed 7 and 14 days after treatment. All rats were examined for the clinical course of EAU, pathologic findings, and immunohistochemistry with confocal microscopy, using antibodies for glia (GFAP), inflammatory cells (ED1, OX42) and MHC class II (OX6). Results: Intravenous injection of BP–PLA NPs significantly decreased clinical and pathologic findings of EAU. Clinical scores of EAU were significantly lower 7 and 14 days after disease in rats receiving BP–PLA NPs than in rats receiving saline or BP (p<0.05). In addition, we found that ocular infiltration of activated T cells and macrophages was markedly decreased after treatment with BM–PLA NPs. The treatment also greatly reduced Müller cell proliferation. Conclusions: These data indicate that intravenous injection of BP–PLA NPs inhibits ocular inflammation in EAU.

Keywords: uveitis–clinical/animal model • inflammation • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×